No products in the cart.
Roxicodone 15mg β The Complete Medical Guide
Introduction to Roxicodone 15mg
Roxicodone 15mg is anΒ immediate-release oxycodone tabletΒ classified as aΒ Schedule II controlled substance. This intermediate-strength formulation is prescribed forΒ moderate to severe acute painΒ in opioid-tolerant patients. As a pure oxycodone product (without acetaminophen), it carries significant risks ofΒ misuse, addiction, and respiratory depression.
Roxicodone 15mg
Roxicodone 15mg is a prescription opioid pain medication used to manage moderate to severe pain. It contains 15mg of oxycodone, a potent narcotic that works by altering the way the brain and nervous system perceive pain. Roxicodone provides fast-acting pain relief, making it ideal for short-term pain management or breakthrough pain. Due to its strength, it should be used only as prescribed by a healthcare provider to avoid risks such as misuse, addiction, or overdose. Always follow your doctorβs guidelines for safe and effective use of Roxicodone 15mg.
Medical Uses & Indications
FDA-Approved Uses
β
Β Moderate to severe acute painΒ requiring opioid analgesia
β
Β Breakthrough cancer painΒ in opioid-tolerant patients
β
Β Postoperative pain management
β
Β Trauma-related pain
Key Clinical Features
β’Β Formulation:Β Immediate-release (no abuse-deterrent properties)
β’Β Onset:Β 15-30 minutes
β’Β Duration:Β 4-6 hours
β’Β Equianalgesic ratio:Β 15mg β 22.5mg oral morphine
β’Β DEA Classification:Β Schedule II (Highest abuse potential)
Pharmacology & Mechanism
Neurochemical Action
β’ Full ΞΌ-opioid receptor agonist
β’ ΞΊ-opioid receptor partial agonist
β’ Inhibits ascending pain pathways
Metabolic Profile
β’Β Hepatic metabolism:Β CYP3A4 (major), CYP2D6 (minor)
β’Β Active metabolite:Β Oxymorphone (via CYP2D6)
β’Β Elimination half-life:Β 3-5 hours
Dosing & Administration
Standard Protocol
β’Β Opioid-tolerant adults:Β 10-15mg every 4-6 hours as needed
β’Β Maximum initial daily dose:Β 60mg
Conversion Guidelines
| Current Opioid | Roxicodone 15mg Equivalent |
|---|---|
| Morphine 22.5mg PO | 15mg |
| Hydrocodone 15mg | 15mg |
| Oxycodone CR 30mg daily | 15mg q12h |
Critical Safety Notes
β Β Not for opioid-naΓ―ve patients
β Β Never crush/chew tabletsΒ (dose dumping risk)
β Β Naloxone co-prescription mandatory
β Β Daily PDMP monitoring recommended
Safety Profile
Common Adverse Effects
β’ Constipation (prophylaxis required)
β’ Nausea/vomiting (30-40%)
β’ Dizziness/sedation
β’ Pruritus (20-25%)
Black Box Warnings
βΒ High potential for addiction and abuse
βΒ Life-threatening respiratory depression
βΒ Accidental ingestion danger
βΒ Neonatal opioid withdrawal syndrome
Risk Mitigation Strategies
Prescribing Safeguards
Limit to 3-5 day supplyΒ for acute pain
State PDMP reviewΒ before each prescription
Written treatment agreement
Frequent follow-up assessments
Patient Education
β’Β Never share medication
β’Β Recognize overdose signs
β’Β Proper storage/disposal
β’Β Avoid all CNS depressants
Clinical Alternatives
For Moderate-Severe Pain
β’Β Oxycodone/acetaminophen combinations
β’Β Hydrocodone immediate-release
β’Β Morphine sulfate IR
Non-Opioid Options
β’Β Ketorolac limited course
β’Β Diclofenac sodium
β’Β Lidocaine patches
Special Population Considerations
| Population | Dosing Adjustment | Monitoring |
|---|---|---|
| Elderly (β₯65) | Start with 5-7.5mg | Increased fall risk |
| Hepatic impairment | 50% dose reduction | LFT monitoring |
| Renal (CrCl<30) | Extended interval (q8h) | Renal function |
| Pediatric | CONTRAINDICATED | – |
Reviews
There are no reviews yet.